Short answer
RIGEL PHARMACEUTICALS INC (RIGL) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Rigel announced financial results for Q3 2026, ended September 30, 2026.
RIGEL PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Rigel announced financial results for Q3 2026, ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1, “Rigel Reports Third Quarter 2026 Financial Results”
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $80.9M, up from $69.5M, driven by product sales growth and $8.6M collaboration revenue
- VEPPANU launched August 13, generating $6.6M initial sales and becoming the key commercial growth catalyst
- Product sales rose 13% to $72.3M, led by REZLIDHIA growth of 20% and offset by GAVRETO decline of 11%
- Net income fell to $13.2M from $27.9M as costs and expenses increased to $63.8M
- 2026 revenue outlook narrowed to $290M-$295M, excluding VEPPANU, while cash declined to $99.3M from $155.0M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RIGEL PHARMACEUTICALS INC 8-K filings
Get the next RIGL 8-K as it lands
Follow RIGL for push alerts, or ask the research agent what this filing means.